Testosterone deficiency as a risk factor for cardiovascular disease

Hormone and Metabolic Research

Volumn 43, Issue 3, 2011, Pages 153-164

  Ullah, M I ^a   Washington, T ^b   Kazi, M ^b   Tamanna, S ^a,c   Koch, C A ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

aging; cardiovascular disease; dyslipidemia; erectile function; libido; metabolic syndrome; testosterone

Indexed keywords

ADIPONECTIN; ANDROGEN RECEPTOR; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTRONE; FATTY ACID; GLUCOSE; GONADORELIN ANTAGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; TESTOSTERONE; TRENBOLONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ALGORITHM; ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ANDROPAUSE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION LOSS; CORONARY ARTERY DISEASE; DEPRESSION; DYSLIPIDEMIA; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; ETHNIC DIFFERENCE; FATIGUE; FRACTURE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HAIR; HEART FAILURE; HEMATOCRIT; HORMONE RESISTANCE; HOT FLUSH; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; HYPOGONADOTROPIC HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIBIDO DISORDER; LIPID METABOLISM; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; MORTALITY; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; RISK BENEFIT ANALYSIS; SLEEP APNEA SYNDROME; SMOKING; TESTOSTERONE BLOOD LEVEL; TREATMENT CONTRAINDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

CARDIOVASCULAR DISEASES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; TESTOSTERONE;

EID: 79952486213     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1270521     Document Type: Review

References (141)

1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986 111 383-390 (Pubitemid 16107280)
2. Barrett-Connor E, Stuenkel C. Hormones and heart disease in women: Heart and Estrogen/Progestin Replacement Study in perspective. J Clin Endocrinol Metab 1999 84 1848-1853 (Pubitemid 30646996)
3. Kienitz T, Allolio B, Strasburger CJ, Quinkler M. Sex-specific regulation of ENaC and androgen receptor in female rat kidney. Horm Metab Res 2009 41 356-362
4. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009 207 318-327
5. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009 5 673-681
6. Borst SE, Quindry JC, Yarrow JF, Conover CF, Powers SK. Testosterone administration induces protection against global myocardial ischemia. Horm Metab Res 2010 42 122-129
7. Nettleship JE, Pugh PJ, Channer KS, Jones T, Jones RD. Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 2007 39 366-371 (Pubitemid 46877853)
8. Yildiz O, Seyrek M. Vasodilating mechanisms of testosterone. Exp Clin Endocrinol Diabetes 2007 115 1-6 (Pubitemid 46293403)
9. Bourghardt J, Wilhelmson AS, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, Ohlsson C, Tivesten A. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 2010 151 5428-5437
10. von Dehn G, von Dehn O, Volker W, Langer C, Weinbauer GF, Behre HM, Nieschlag E, Assmann G, von Eckardstein A. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res 2001 33 110-114 (Pubitemid 32231992)
11. Tripathy D, Shah P, Lakshmy R, Reddy KS. Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 1998 30 642-645 (Pubitemid 28523429)
12. Muller M, den Tonkelaar I, Thijssen JH, Grobbee DE, van der Schouw YT. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol 2003 149 583-589 (Pubitemid 38054704)
13. Kazi M, Geraci SA, Koch CA. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am J Med 2007 120 835-840 (Pubitemid 47451287)
14. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001 86 724-731 (Pubitemid 32207487)
15. Liu PP, Fukuoka M. Sex hormones as novel risk biomarkers for atherosclerosis in peripheral vascular disease. J Am Coll Cardiol 2007 50 1077-1079
16. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006 60 762-769 (Pubitemid 43881152)
17. Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007 92 4241-4247 (Pubitemid 350074738)
18. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009 5 427-448
19. Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi IT, Kula K, Punab M, Boonen S, Vanderschueren D;, European Male Aging Study Group. Hypothalamic-pituitary- testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008 93 2737-2745 (Pubitemid 352008544)
20. Veldhuis JD. Aging and hormones of the hypothalamo-pituitary axis: gonadotropic axis in men and somatotropic axes in men and women. Ageing Res Rev 2008 7 189-208
21. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005 26 833-876 (Pubitemid 41428540)
22. Vgontzas AN, Bixler EO, Chrousos GP. Obesity-related sleepiness and fatigue: the role of the stress system and cytokines. Ann NY Acad Sci 2006 1083 329-344 (Pubitemid 44955481)
23. Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res 2010 42 621-626
24. Diamanti-Kandarakis E, Palioura E, Kandarakis SA, Koutsilieris M. The impact of endocrine disruptors on endocrine targets. Horm Metab Res 2010 42 543-552
25. Hanefeld MLW. Das metabolische Syndrom. Dt Gesundh-Wesen 1981 36 545-551
26. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH. The metabolic syndrome. Endocr Rev 2008 29 777-822
27. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M. Testosterone and Metabolic Syndrome: A Meta-Analysis Study. J Sex Med 2011 Jan; 8 (1) 272-283
28. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2010 Oct 24. doi: 10.1111/j.1365-2605.2010.01117
29. Corona G, Monami M, Rastrelli G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Is Metabolic Syndrome a Useless Category in Subjects with High Cardiovascular Risk? Results from a Cohort Study in Men with Erectile Dysfunction. J Sex Med 2010 Nov 22. doi: 10.1111/j.1743-6109.2010.02126
30. Schutte AE, Schutte R, Huisman HW, Rooyen JM, Malan L, Olckers A, Malan NT. Classifying Africans with the metabolic syndrome. Horm Metab Res 2009 41 79-85
31. Hromadova M, Hacik T, Malatinsky E, Riecansky I. Alterations of lipid metabolism in men with hypotestosteronemia. Horm Metab Res 1991 23 392-394
32. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 2004 109 2074-2079 (Pubitemid 38620214)
33. Makinen J, Jarvisalo MJ, Pollanen P, Perheentupa A, Irjala K, Koskenvuo M, Mkinen J, Huhtaniemi I, Raitakari OT. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005 45 1603-1608 (Pubitemid 40704493)
34. Tomaszewski M, Charchar FJ, Maric C, Kuzniewicz R, Gola M, Grzeszczak W, Samani NJ, Zukowska-Szczechowska E. Association between lipid profile and circulating concentrations of estrogens in young men. Atherosclerosis 2009 203 257-262
35. Corona G, Boddi V, Balercia G, Rastrelli G, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010 7 1547-1556
36. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Androl 2008 29 534-539
37. Yeap BB. Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 2009 5 113-121
38. Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS. Plasma levels of sex hormone-binding globulin, corticosteroid-binding globulin and cortisol in overweight subjects who develop impaired fasting glucose: a 3-year prospective study. Horm Metab Res 2009 41 255-259
39. Chubb SA, Hyde Z, Almeida OP, Flicker L, Norman PE, Jamrozik K, Hankey GJ, Yeap BB. Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur J Endocrinol 2008 158 785-792 (Pubitemid 351837366)
40. Forst T, Hohberg C, Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009 41 123-131
41. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004 27 1036-1041 (Pubitemid 38579762)
42. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007 92 3568-3572 (Pubitemid 47435336)
43. Kupelian V, Hayes FJ, Link CL, Rosen R, McKinlay JB. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab 2008 93 3403-3410
44. Xita N, Milionis HJ, Galidi A, Lazaros L, Katsoulis K, Elisaf MS, Georgiou I, Tsatsoulis A. The (TAAAA)n Polymorphism of the SHBG Gene in Men with the Metabolic Syndrome. Exp Clin Endocrinol Diabetes 2010 Aug 5
45. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004 89 5462-5468 (Pubitemid 39518427)
46. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007 30 234-238 (Pubitemid 46198324)
47. Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 1990 71 929-931
48. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990 39 897-901 (Pubitemid 20293933)
49. Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD, Sweetnam PM, Marks V, Teale D, Riad-Fahmy D. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol 1987 126 647-657 (Pubitemid 17142236)
50. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R, Capelli M, Bortoluzzi L. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991 40 101-104
51. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L. Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 1992 35 173-177
52. Friedrich N, Rosskopf D, Brabant G, Völzke H, Nauck M, Wallaschofski H. Associations of anthropometric parameters with serum TSH, prolactin, IGF-I, and testosterone levels: results of the study of health in Pomerania (SHIP). Exp Clin Endocrinol Diabetes 2010 118 266-273
53. Maric C, Forsblom C, Thorn L, Waden J, Groop PH. Association between testosterone, estradiol and sex hormone binding globulin levels in men with type 1 diabetes with nephropathy. Steroids 2010 75 772-778
54. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 118 2010 167-171
55. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, Jerums G. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008 93 1834-1840 (Pubitemid 351656526)
56. Miller KK, Biller BM, Schaub A, Pulaski-Liebert K, Bradwin G, Rifai N, Klibanski A. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab 2007 92 2474-2479 (Pubitemid 47037345)
57. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006 154 899-906 (Pubitemid 43997730)
58. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005 90 2636-2641 (Pubitemid 40686302)
59. Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza RA. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007 30 1972-1978 (Pubitemid 47219403)
60. Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, Shah NS. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010 16 570-576
61. Ishikawa T, Yamaguchi K, Kondo Y, Takenaka A, Fujisawa M. Metabolic syndrome in men with Klinefelter's syndrome. Urology 2008 71 1109-1113
62. Bojesen A, Kristensen K, Birkebaek NH, Fedder J, Mosekilde L, Bennett P, Laurberg P, Frystyk J, Flyvbjerg A, Christiansen JS, Gravholt CH. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 2006 29 1591-1598 (Pubitemid 44127586)
63. Bojesen A, Juul S, Birkebaek N, Gravholt CH. Increased mortality in Klinefelter syndrome. J Clin Endocrinol Metab 2004 89 3830-3834 (Pubitemid 39071480)
64. Pei D, Sheu WH, Jeng CY, Liao WK, Fuh MM. Insulin resistance in patients with Klinefelter's syndrome and idiopathic gonadotropin deficiency. J Formos Med Assoc 1998 97 534-540 (Pubitemid 28414523)
65. Dati E, Baroncelli GI, Mora S, Russo G, Baldinotti F, Parrini D, Erba P, Simi P, Bertelloni S. Body composition and metabolic profile in women with complete androgen insensitivity syndrome. Sex Dev 2009 3 188-193
66. Sievers C, Klotsche J, Pieper L, Schneider HJ, Mrz W, Wittchen HU, Stalla GK, Mantzoros C. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol 2010 163 699-708
67. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 2007 50 2076-2084 (Pubitemid 47373864)
68. Torrens JI, Sutton-Tyrrell K, Zhao X, Matthews K, Brockwell S, Sowers M, Santoro N. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation. Menopause 2009 16 257-264
69. Yanase T, Fan W, Kyoya K, Min L, Takayanagi R, Kato S, Nawata H. Androgens and metabolic syndrome: lessons from androgen receptor knock out (ARKO) mice. J Steroid Biochem Mol Biol 2008 109 254-257
70. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010 96 1821-1825
71. Akishita M, Hashimoto M, Ohike Y, Ogawa S, Iijima K, Eto M, Ouchi Y. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res 2007 30 1029-1034
72. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008 93 68-75
73. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res 1999 84 813-819 (Pubitemid 29181488)
74. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007 116 2427-2434 (Pubitemid 350145077)
75. Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007 116 2694-2701 (Pubitemid 350291241)
76. Keating NL, O'Malley AJ, Smith MR. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer. J Clin Oncol 2006 24 4448-4456 (Pubitemid 46630983)
77. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007 110 1493-1500 (Pubitemid 47463063)
78. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions. J Clin Oncol 2007 25 2420-2425 (Pubitemid 46999213)
79. Tsai HK, D'Amico AV, Sadetsky N, Chen M-H, Carroll PR. Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality. J Natl Cancer Inst 2007 99 1516-1524 (Pubitemid 351767235)
80. Anthony VDA, Ming-Hui C, Andrew AR, Marian L, Philip WK. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 2008 113 3290-3297
81. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010 60 194-201
82. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004 63 742-745 (Pubitemid 38479421)
83. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002 87 599-603 (Pubitemid 34158224)
84. Eri LM, Urdal P, Bechensteen AG. Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995 154 100-104
85. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006 91 1305-1308
86. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006 24 3979-3983 (Pubitemid 46630747)
87. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008 15 565-576
88. Ahima RS. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006 14 242S-249S
89. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006 64 355-365
90. Lin HY, Xu Q, Yeh S, Wang RS, Sparks JD, Chang C. Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes 2005 54 1717-1725 (Pubitemid 40770762)
91. Li H, Matheny M, Nicolson M, Tumer N, Scarpace PJ. Leptin gene expression increases with age independent of increasing adiposity in rats. Diabetes 1997 46 2035-2039 (Pubitemid 27512092)
92. Luukkaa V, Pesonen U, Huhtaniemi I, Lehtonen A, Tilvis R, Tuomilehto J, Koulu M, Huupponen R. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998 83 3243-3246 (Pubitemid 28500967)
93. Pejovic S, Vgontzas AN, Basta M, Tsaoussoglou M, Zoumakis E, Vgontzas A, Bixler EO, Chrousos GP. Leptin and hunger levels in young healthy adults after one night of sleep loss. J Sleep Res 2010 19 552-558
94. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001 56 702-708 (Pubitemid 32588221)
95. Axelsson J, Ingre M, Akerstedt T, Holmback U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab 2005 90 4530-4535 (Pubitemid 41159338)
96. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Neuroendocrine Dysfunction in Sleep Apnea: Reversal by Continuous Positive Airways Pressure Therapy. J Clin Endocrinol Metab 1989 68 352-358 (Pubitemid 19052876)
97. Saini J, Krieger J, Brandenberger G, Wittersheim G, Simon C, Follenius M. Continuous positive airway pressure treatment. Effects on growth hormone, insulin and glucose profiles in obstructive sleep apnea patients. Horm Metab Res 1993 25 375-381 (Pubitemid 23208107)
98. Gianotti L, Pivetti S, Lanfranco F, Tassone F, Navone F, Vittori E, Rossetto R, Gauna C, Destefanis S, Grottoli S, De Giorgi R, Gai V, Ghigo E, Maccario M. Concomitant impairment of growth hormone secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome. J Clin Endocrinol Metab 2002 87 5052-5057 (Pubitemid 35316345)
99. Makino S, Fujiwara M, Suzukawa K, Handa H, Fujie T, Ohtaka Y, Komatsu Y, Aoki Y, Maruyama H, Terada Y, Hashimoto K, Sugimoto T. Visceral obesity is associated with the metabolic syndrome and elevated plasma retinol binding protein-4 level in obstructive sleep apnea syndrome. Horm Metab Res 2009 41 221-226
100. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, Lavie P. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab 2002 87 3394-3398 (Pubitemid 34816395)
101. Gonzalez-Santos MR, Gaja-Rodriguez OV, Alonso-Uriarte R, Sojo-Aranda I, Cortes-Gallegos V. Sleep deprivation and adaptive hormonal responses of healthy men. Arch Androl 1989 22 203-207
102. Penev PD. Association between sleep and morning testosterone levels in older men. Sleep 2007 30 427-432 (Pubitemid 46668699)
103. Matsumoto AM, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, Bremner WJ. Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 1985 22 713-721 (Pubitemid 15046172)
104. Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR, Handelsman DJ. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003 88 3605-3613 (Pubitemid 37034502)
105. Schneider BK, Pickett CK, Zwillich CW, Weil JV, McDermott MT, Santen RJ, Varano LA, White DP. Influence of testosterone on breathing during sleep. J Appl Physiol 1986 61 618-623 (Pubitemid 16025218)
106. Luboshitzky R, Lavie L, Shen-Orr Z, Lavie P. Pituitary-gonadal function in men with obstructive sleep apnea. The effect of continuous positive airways pressure treatment. Neuro Endocrinol Lett 2003 24 463-467 (Pubitemid 38035098)
107. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005 63 381-394 (Pubitemid 41442332)
108. Baum NH, Crespi CA. Testosterone replacement in elderly men. Geriatrics 2007 62 15-18 (Pubitemid 47429274)
109. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009 30 293-342
110. Stanworth RD, Kapoor D, Channer KS, Jones TH. Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care 2009 32 541-546
111. Kapoor D, Channer KS, Jones TH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res 2008 5 135-137 (Pubitemid 351839286)
112. Morley JE. Testosterone replacement and the physiologic aspects of aging in men. Mayo Clin Proc 2000 75 Suppl S83-S87
113. Moore C, Huebler D, Zimmermann T, Heinemann LA, Saad F, Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004 46 80-87 (Pubitemid 38748514)
114. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2010 95 2536-2559
115. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Androl 2009 32 1-10
116. Jannini EA, Screponi E, Carosa E, Pepe M, Lo Giudice F, Trimarchi F, Benvenga S. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl 1999 22 385-392
117. Carosa E, Benvenga S, Trimarchi F, Lenzi A, Pepe M, Simonelli C, Jannini EA. Sexual inactivity results in reversible reduction of LH bioavailability. Int J Impot Res 2002 14 93-99 discussion 100
118. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N, Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000 85 2839-2853 (Pubitemid 32269162)
119. Jockenhovel F, Minnemann T, Schubert M, Freude S, Hbler D, Schumann C, Christoph A, Gooren L, Ernst M. Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. Aging Male 2009 12 113-118
120. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010 73 602-612
121. Wackers FJ, Young LH. Lessons learned from the detection of ischemia in asymptomatic diabetics (DIAD) study. J Nucl Cardiol 2009 16 855-859
122. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE, American Heart Association Committee on Cardiovascular Imaging and Intervention; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging, Council on Clinical Cardiology. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006 114 1761-1791 (Pubitemid 44607126)
123. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants. Am J Epidemiol 1997 146 609-617 (Pubitemid 27454548)
124. Berg G, Schreier L, Geloso G, Otero P, Nagelberg A, Levalle O. Impact on lipoprotein profile after long-term testosterone replacement in hypogonadal men. Horm Metab Res 2002 34 87-92 (Pubitemid 34211021)
125. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002 87 136-143 (Pubitemid 34084682)
126. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000 102 1906-1911
127. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997 82 3793-3796 (Pubitemid 27509374)
128. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993 77 776-779 (Pubitemid 23298665)
129. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006 91 1995-2010 (Pubitemid 43854972)
130. Khera M, Lipshultz LI. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007 34 549-553 vi (Pubitemid 350029947)
131. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007 109 536-541 (Pubitemid 46190961)
132. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloa ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007 82 29-39 (Pubitemid 46036319)
133. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999 84 3469-3478 (Pubitemid 30645193)
134. Santamaria JD, Prior JC, Fleetham JA. Reversible reproductive dysfunction in men with obstructive sleep apnoea. Clin Endocrinol (Oxf) 1988 28 461-470
135. Carruthers M. Time for international action on treating testosterone deficiency syndrome. Aging Male 2009 12 21-28
136. Carruthers M. The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. J Sex Med 2008 5 998-1012 (Pubitemid 351472215)
137. Crabbe P, Bogaert V, De Bacquer D, Goemaere S, Zmierczak H, Kaufman JM. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab 2007 92 3604-3610 (Pubitemid 47435345)
138. Wang C, Christenson P, Swerdloff R. Editorial: Clinical relevance of racial and ethnic differences in sex steroids. J Clin Endocrinol Metab 2007 92 2433-2435 (Pubitemid 47037338)
139. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA. Serum estrogen, but not testosterone, levels differ between black and
140. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, Pike MC, Henderson BE. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992 339 887-889
141. Marks LS, Hess DL, Dorey FJ, Macairan ML. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology 2006 68 337-341 (Pubitemid 44175511)